Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Core Insights - Exicure, Inc. is set to present at the 2026 Tandem Meetings, showcasing data from its Phase 2 trial of burixafor for multiple myeloma patients undergoing autologous hematopoietic cell transplantation [1][2] Group 1: Company Overview - Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematologic diseases, with its lead program being burixafor, a selective antagonist of the CXCR4 receptor [5] - Burixafor aims to enhance stem cell mobilization into peripheral blood, facilitating collection for autologous hematopoietic cell transplantation [5][6] Group 2: Clinical Trial Insights - The Phase 2 trial (NCT05561751) evaluated burixafor's effectiveness in mobilizing hematopoietic progenitor cells by blocking CXCR4, which retains stem cells in the bone marrow [2][3] - The trial reported that 89.7% of patients met the primary endpoint, demonstrating reliable mobilization and a favorable safety profile when burixafor was used in combination with propranolol and G-CSF [3][4] Group 3: Future Directions - Exicure is exploring burixafor's potential in other conditions, including sickle cell disease and acute myeloid leukemia, where it may help mobilize malignant cells for more effective chemotherapy [6]